Literature DB >> 18508221

Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues.

Susan Moyher Noworolski1, Daniel B Vigneron, Albert P Chen, John Kurhanewicz.   

Abstract

PURPOSE: To compare peak enhancement (PE), determined from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and the magnetic resonance (MR) directionally-averaged apparent diffusion coefficient (<D>) in glandular versus stromal prostatic tissues and, with this comparison, to infer if the hypothesis that gadolinium-DTPA (Gd-DTPA) does not enter healthy glands or ducts is plausible.
MATERIALS AND METHODS: MRI, MR spectroscopic imaging, DCE MRI and MR diffusion were evaluated in 17 untreated subjects with suspected or proven prostate cancer. PE and <D> were compared in glandular-ductal tissues [normal peripheral zone and glandular benign prostatic hyperplasia (BPH)] and stromal-low ductal tissues (central gland/mixed BPH and stromal BPH).
RESULTS: The glandular-ductal tissues had lower PE [125+/-6.4 (% baseline)] and higher <D> [1.57+/-0.15 (s/10(-3) mm2)] than the stromal-low ductal tissues [PE=132+/-5.5 (% baseline) (P< .0008), <D>=1.18+/-0.20 (s/10(-3) mm2) (P< 1 x 10(-8))]. A statistical model based upon stepwise regression was generated and completely separated the tissue types: ductal Measure = 448+669 x<D> (s/10(-3) mm2)-10.7 x PE (1/%), R2=1.0 and P<8 x 10(-10).
CONCLUSIONS: The very different MR results in the glandular-ductal versus stromal-low ductal tissues suggest that these tissues have different underlying structure. These results support the hypothesis that Gd-DTPA does not enter healthy prostatic glands or ducts. This may explain the higher PE and lower <D> that previously have been reported in prostate cancer versus healthy tissue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508221      PMCID: PMC2610684          DOI: 10.1016/j.mri.2008.01.033

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  36 in total

1.  Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors.

Authors:  S J Nelson
Journal:  Magn Reson Med       Date:  2001-08       Impact factor: 4.668

2.  Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging.

Authors:  A A Schricker; J M Pauly; J Kurhanewicz; M G Swanson; D B Vigneron
Journal:  Magn Reson Med       Date:  2001-12       Impact factor: 4.668

3.  Single-shot fast spin-echo diffusion tensor imaging of the brain and spine with head and phased array coils at 1.5 T and 3.0 T.

Authors:  Duan Xu; Roland G Henry; Pratik Mukherjee; Lucas Carvajal; Steven P Miller; A James Barkovich; Daniel B Vigneron
Journal:  Magn Reson Imaging       Date:  2004-07       Impact factor: 2.546

4.  Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate.

Authors:  Jurgen J Fütterer; Tom W J Scheenen; Henkjan J Huisman; Dennis W J Klomp; Ferdi A van Dorsten; Christina A Hulsbergen-van de Kaa; J Alfred Witjes; Arend Heerschap; Jelle O Barentsz
Journal:  Invest Radiol       Date:  2004-11       Impact factor: 6.016

5.  Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue.

Authors:  Keyanoosh Hosseinzadeh; Samuel David Schwarz
Journal:  J Magn Reson Imaging       Date:  2004-10       Impact factor: 4.813

6.  Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound.

Authors:  H Ito; K Kamoi; K Yokoyama; K Yamada; T Nishimura
Journal:  Br J Radiol       Date:  2003-09       Impact factor: 3.039

7.  Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging.

Authors:  Marc R Engelbrecht; Henkjan J Huisman; Robert J F Laheij; Gerrit J Jager; Geert J L H van Leenders; Christina A Hulsbergen-Van De Kaa; Jean J M C H de la Rosette; Johan G Blickman; Jelle O Barentsz
Journal:  Radiology       Date:  2003-08-27       Impact factor: 11.105

8.  Enhancement patterns of prostate cancer in dynamic MRI.

Authors:  Paolo Preziosi; Antonio Orlacchio; Guido Di Giambattista; Paolo Di Renzi; Luigi Bortolotti; Alfredo Fabiano; Enrico Cruciani; Patrizio Pasqualetti
Journal:  Eur Radiol       Date:  2002-11-14       Impact factor: 5.315

Review 9.  Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer.

Authors:  John Kurhanewicz; Mark G Swanson; Sarah J Nelson; Daniel B Vigneron
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

10.  Challenges in dynamic contrast-enhanced MRI imaging of cervical lymph nodes to detect metastatic disease.

Authors:  Susan M Noworolski; Nancy J Fischbein; Michael J Kaplan; Ying Lu; Sarah J Nelson; Lucas Carvajal; Roland G Henry
Journal:  J Magn Reson Imaging       Date:  2003-04       Impact factor: 4.813

View more
  29 in total

1.  Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy.

Authors:  Piotr Kozlowski; Silvia D Chang; Ran Meng; Burkhard Mädler; Robert Bell; Edward C Jones; S Larry Goldenberg
Journal:  Magn Reson Imaging       Date:  2010-04-13       Impact factor: 2.546

2.  Classification of suspicious lesions on prostate multiparametric MRI using machine learning.

Authors:  Deukwoo Kwon; Isildinha M Reis; Adrian L Breto; Yohann Tschudi; Nicole Gautney; Olmo Zavala-Romero; Christopher Lopez; John C Ford; Sanoj Punnen; Alan Pollack; Radka Stoyanova
Journal:  J Med Imaging (Bellingham)       Date:  2018-09-06

3.  Assessment of prostate imaging reporting and data system version 2.1 false-positive category 4 and 5 lesions in clinically significant prostate cancer.

Authors:  Xiangyu Wang; Weizong Liu; Yi Lei; Guangyao Wu; Fan Lin
Journal:  Abdom Radiol (NY)       Date:  2021-03-12

4.  Quantitative effects of acquisition duration and temporal resolution on the measurement accuracy of prostate dynamic contrast-enhanced MRI data: a phantom study.

Authors:  Silvin Paul Knight; Jacinta Elizabeth Browne; James Frances Mary Meaney; Andrew John Fagan
Journal:  MAGMA       Date:  2017-04-10       Impact factor: 2.310

5.  Magnetic resonance imaging for prostate cancer clinical application.

Authors:  Bing Li; Yong Du; Hanfeng Yang; Yayong Huang; Jun Meng; Dongmei Xiao
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

6.  IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model.

Authors:  Devkumar Mustafi; Sophie-Charlotte Gleber; Jesse Ward; Urszula Dougherty; Marta Zamora; Erica Markiewicz; David C Binder; Tatjana Antic; Stefan Vogt; Gregory S Karczmar; Aytekin Oto
Journal:  AJR Am J Roentgenol       Date:  2015-09       Impact factor: 3.959

7.  Detection of Clinically Significant Prostate Cancer: Short Dual-Pulse Sequence versus Standard Multiparametric MR Imaging-A Multireader Study.

Authors:  Borna K Barth; Pieter J L De Visschere; Alexander Cornelius; Carlos Nicolau; Hebert Alberto Vargas; Daniel Eberli; Olivio F Donati
Journal:  Radiology       Date:  2017-03-27       Impact factor: 11.105

Review 8.  Advancements in MR imaging of the prostate: from diagnosis to interventions.

Authors:  David Bonekamp; Michael A Jacobs; Riham El-Khouli; Dan Stoianovici; Katarzyna J Macura
Journal:  Radiographics       Date:  2011 May-Jun       Impact factor: 5.333

9.  An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes.

Authors:  Radka Stoyanova; Felix Chinea; Deukwoo Kwon; Isildinha M Reis; Yohann Tschudi; Nestor A Parra; Adrian L Breto; Kyle R Padgett; Alan Dal Pra; Matthew C Abramowitz; Oleksandr N Kryvenko; Sanoj Punnen; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-13       Impact factor: 7.038

Review 10.  Imaging techniques for prostate cancer: implications for focal therapy.

Authors:  Baris Turkbey; Peter A Pinto; Peter L Choyke
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.